Literature DB >> 32354495

Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.

Patrizio Armeni1, Ludovica Borsoi2, Giulia Fornaro2, Claudio Jommi2, Francesco Grossi3, Francesco Costa2.   

Abstract

PURPOSE: The aim of this study was to evaluate the cost-effectiveness and net monetary benefit of durvalumab consolidation therapy compared with no consolidation therapy after chemoradiotherapy in patients with stage III non-small cell lung cancer with programmed cell death 1 ligand 1 expression ≥1% from the Italian National Health Service perspective.
METHODS: We developed a 12-month decision tree combined with a lifetime cohort Markov model in which patients were assigned to receive durvalumab consolidation therapy or active follow-up (Italian standard of care) after chemoradiotherapy to compare cost-effectiveness and net monetary benefit of the two strategies during a 40-year period. Clinical outcomes data were obtained from the respective clinical trials and extrapolated using survival analysis; cost data were derived from Italian official sources and relevant real-world studies. The incremental cost-effectiveness ratio, incremental cost-utility ratio, and incremental net monetary benefit were computed and compared against a 16,372 € per quality-adjusted life-year (QALY) willingness-to-pay threshold. We performed deterministic sensitivity analysis and probabilistic sensitivity analysis to assess how uncertainty affected results; we also performed scenario analyses to compare results under different pricing settings.
FINDINGS: In the base-case scenario, during a 40-year period, the total costs for patients treated with durvalumab consolidation therapy and active follow-up were €59,860 and €49,840 respectively; life-years gained were 3.47 and 3.31, respectively; and QALYs gained were 2.73 and 2.50, respectively, with an incremental cost-effectiveness ratio of €62,131 per life-year, an incremental cost-utility ratio of €42,322 per QALY, and an incremental net monetary benefit of €-6,144. We found that durvalumab was cost-effective (incremental net monetary benefit = 0) when a discount of 13% and 30% on its official price was applied, considering all other drugs priced according to official or maximum selling prices, respectively. Results were most sensitive to the progression-free survival rate for durvalumab and active follow-up, health utility in progression-free state, and price of subsequent treatments. IMPLICATIONS: Our analysis indicates that durvalumab consolidation is cost-effective when a discount is applied on its official price. These results suggest that durvalumab may deliver an incremental health benefit with a contained upfront cost during a 40-year period, from the Italian National Health Service perspective, providing added value in a potentially curative care setting.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cost-effectiveness analysis; durvalumab; immune-checkpoint inhibitors; net monetary benefit analysis; non–small cell lung cancer

Mesh:

Substances:

Year:  2020        PMID: 32354495     DOI: 10.1016/j.clinthera.2020.03.012

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  4 in total

1.  Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.

Authors:  Will Dunlop; Marjolijn van Keep; Peter Elroy; Ignacio Diaz Perez; Mario J N M Ouwens; Tina Sarbajna; Yiduo Zhang; Alastair Greystoke
Journal:  Pharmacoecon Open       Date:  2021-09-16

2.  Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage Ⅲ nsclc in china.

Authors:  Xiaotong Jiang; Jinyu Chen; Min Zheng; Hanxue Jia
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

3.  Cost-effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non-small cell lung cancer.

Authors:  Alessandra Buja; Giulia Pasello; Marco Schiavon; Giuseppe De Luca; Michele Rivera; Claudia Cozzolino; Anna De Polo; Manuela Scioni; Alberto Bortolami; Vincenzo Baldo; PierFranco Conte
Journal:  Thorac Cancer       Date:  2022-08-15       Impact factor: 3.223

4.  Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.

Authors:  Abed Agbarya; Walid Shalata; Alfredo Addeo; Andriani Charpidou; Kristof Cuppens; Odd Terje Brustugun; Mirjana Rajer; Marco Jakopovic; Mihai V Marinca; Adam Pluzanski; Jeroen Hiltermann; António Araújo
Journal:  J Clin Med       Date:  2022-03-21       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.